Industry Trends
DEA’s Schedule III Cannabis Order: A Free-For-All for Telehealth Platforms, or the Perfect Setup for the Entire Industry?
As the industry’s (more than justified) excitement over last week’s rescheduling announcement begins to subside, the regulatory reality is settling in.
